IXICO (IXI) Share Price, News & Analysis

Company Overview

IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients. Our integrated technology offering encompasses every stage of clinical drug development through to post marketing surveillance and we continue to invest in infrastructure and innovation to support our ambitious growth strategy. Our competitive advantage is our dedication to address complex unmet clinical research needs by partnering and collaborating with clients and academic partners early in the drug development cycle to identify and validate promising new imaging and digital biomarkers.

Key Stats

• Today's Range: 10.50 to 12.50
• 50-Day Range: 7.51 to 12.50
• 52-Week Range: 6.45 to 13
• Volume: 169,204 shs
• Average Volume: 41,883 shs
• Market Capitalization: £10.19 million
• P/E Ratio: N/A
• Dividend Yield: 1.27%
• Price Target: N/A
• Consensus Rating: N/A

IXI Stock Analysis - Frequently Asked Questions

How have IXI shares performed this year?

IXICO's stock was trading at GBX 12.50 at the beginning of the year. Since then, IXI shares have decreased by 12.0% and is now trading at GBX 11.
View the best growth stocks for 2025 here.

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) released its earnings results on Tuesday, May, 20th. The company reported ($1.11) earnings per share (EPS) for the quarter. IXICO had a negative trailing twelve-month return on equity of 19.14% and a negative net margin of 31.10%.

How do I buy shares of IXICO?

Shares of IXI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IXICO investors own include BioNTech (BNTX), Benefitfocus (BNFT), Grayscale Bitcoin Trust ETF (GBTC), Motif Bio (MTFB), Pfizer (PFE), Tesla (TSLA) and VEON (VEON).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:IXI
• CIK: N/A
• Web: ixico.com
• Phone: +44-20-37637499
• Fax: N/A
• Employees: 89
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.38
• Net Income: -£3.58 million
• Net Margins: -31.10%
• Pretax Margin: N/A
• Return on Equity: -19.14%
• Return on Assets: -10.40%

Debt

• Debt-to-Equity Ratio: 3.32
• Current Ratio: 2.85
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: £11.50 million
• Price / Sales: 0.89
• Cash Flow: GBX 4.89 per share
• Price / Cash Flow: 2.25
• Book Value: GBX 19.57 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 92,668,597
• Free Float: N/A
• Market Cap: £10.19 million
• Optionable: Not Optionable
• Beta: 0.86